Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
N/A
1(50.0%)
2Total
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04979195Completed

Acute Kidney Injury Among COVID-19 Positive Patients

Role: lead

NCT04665830Phase 3Completed

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Role: lead

NCT04542954Completed

Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East

Role: lead

NCT03861637Not ApplicableCompleted

Impact of Full Correction of PTA in Renal Transplant Recipients

Role: lead

All 4 trials loaded